Product Description
ACTR707 is derived from Unums novel proprietary Antibody-Coupled T cell Receptor (ACTR) platform.
Mechanisms of Action: CD28 Binder
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cogent Biosciences
Company Location: CAMBRIDGE MA 02140
Company CEO: Andrew Robbins
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ATTCK-20-03 | P1 |
Terminated |
Lymphoma |
2020-09-21 |
42% |